FDA
-
-
-
-
-
-
-
ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits
-
-
-
-
-
-
-
RespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition
-
-
-
-
-
-
-
RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmacoresistant Epilepsy and Chronic Pain
-
-
-
-
-
-
-
RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference
-
-
-
-
-
-
-
RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation, Inc. and Entry into a License Agreement for GABA(A) Receptor Allosteric Ne
-
-
-
-
-
-
-
RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
-
-
-
-
-
-
-
RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc.
-
251,768 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All